Shots:

• The company resubmits the sBLA to the FDA for updating the dosing frequency for Keytruda- to include a 400mg dose infused over 30mis q6w- in addition to the currently approved dose of 200mg q3w
• Merck has filed the resubmission addressing the Complete Response Letter issued in Febr’2020 and filed sBLA across all indications of Keytruda- including monothx. and combination therapy
• Keytruda is a mAb blocks the interaction between PD-1 and its ligands- PD-L1 and PD-L2- thus activating T lymphocytes affecting both tumor cells and healthy cells

Click here ­to­ read full press release/ article 

Ref: Merck | Image: Merck